157 related articles for article (PubMed ID: 30928630)
1. CS2164 suppresses acute myeloid leukemia cell growth via inhibiting VEGFR2 signaling in preclinical models.
Deng M; Zhao H; Chen Q; Zhao J; Shi Y; Yu L; Fang Z; Xu B
Eur J Pharmacol; 2019 Jun; 853():193-200. PubMed ID: 30928630
[TBL] [Abstract][Full Text] [Related]
2. CS2164 exerts an antitumor effect against human Non-Hodgkin's lymphomas in vitro and in vivo.
Deng M; Shi Y; Chen K; Zhao H; Wang Y; Xie S; Zhao J; Luo Y; Fang Z; Fan Y; Xu B
Exp Cell Res; 2018 Aug; 369(2):356-362. PubMed ID: 29864401
[TBL] [Abstract][Full Text] [Related]
3. Apatinib exhibits cytotoxicity toward leukemia cells by targeting VEGFR2-mediated prosurvival signaling and angiogenesis.
Deng M; Zha J; Zhao H; Jia X; Shi Y; Li Z; Fu G; Yu L; Fang Z; Xu B
Exp Cell Res; 2020 May; 390(1):111934. PubMed ID: 32126236
[TBL] [Abstract][Full Text] [Related]
4. CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency.
Zhou Y; Shan S; Li ZB; Xin LJ; Pan DS; Yang QJ; Liu YP; Yue XP; Liu XR; Gao JZ; Zhang JW; Ning ZQ; Lu XP
Cancer Sci; 2017 Mar; 108(3):469-477. PubMed ID: 28004478
[TBL] [Abstract][Full Text] [Related]
5. Antitumor and immunomodulatory effects of a novel multitarget inhibitor, CS2164, in mouse hepatocellular carcinoma models.
Zhou Y; Fu C; Kong Y; Pan D; Wang Y; Huang S; Li Z; Ning Z; Lu X; Shan S; Xin L
Anticancer Drugs; 2019 Oct; 30(9):909-916. PubMed ID: 30998512
[TBL] [Abstract][Full Text] [Related]
6. Apatinib exhibits anti-leukemia activity in preclinical models of acute lymphoblastic leukemia.
Deng M; Zha J; Jiang Z; Jia X; Shi Y; Li P; Chen XL; Fang Z; Du Z; Xu B
J Transl Med; 2018 Feb; 16(1):47. PubMed ID: 29490645
[TBL] [Abstract][Full Text] [Related]
7. VEGFR2-Mediated Reprogramming of Mitochondrial Metabolism Regulates the Sensitivity of Acute Myeloid Leukemia to Chemotherapy.
Nóbrega-Pereira S; Caiado F; Carvalho T; Matias I; Graça G; Gonçalves LG; Silva-Santos B; Norell H; Dias S
Cancer Res; 2018 Feb; 78(3):731-741. PubMed ID: 29229602
[TBL] [Abstract][Full Text] [Related]
8. SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias.
Bourrié B; Brassard DL; Cosnier-Pucheu S; Zilberstein A; Yu K; Levit M; Morrison JG; Perreaut P; Jegham S; Hilairet S; Bouaboula M; Penarier G; Guiot C; Larroze-Chicot P; Laurent G; Demur C; Casellas P
Leuk Lymphoma; 2013 Jul; 54(7):1488-99. PubMed ID: 23121564
[TBL] [Abstract][Full Text] [Related]
9. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
[No Abstract] [Full Text] [Related]
10. Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth.
Qin L; Tian Y; Yu Z; Shi D; Wang J; Zhang C; Peng R; Chen X; Liu C; Chen Y; Huang W; Deng W
Oncotarget; 2016 Jan; 7(2):1395-407. PubMed ID: 26593251
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.
Yang LL; Li GB; Ma S; Zou C; Zhou S; Sun QZ; Cheng C; Chen X; Wang LJ; Feng S; Li LL; Yang SY
J Med Chem; 2013 Feb; 56(4):1641-55. PubMed ID: 23362959
[TBL] [Abstract][Full Text] [Related]
12. A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia.
Chen Y; Xie X; Wu A; Wang L; Hu Y; Zhang H; Li Y
J Exp Clin Cancer Res; 2018 Jan; 37(1):12. PubMed ID: 29357910
[TBL] [Abstract][Full Text] [Related]
13. Napabucasin (BBI608) eliminate AML cells in vitro and in vivo via inhibition of Stat3 pathway and induction of DNA damage.
Bi S; Chen K; Feng L; Fu G; Yang Q; Deng M; Zhao H; Li Z; Yu L; Fang Z; Xu B
Eur J Pharmacol; 2019 Jul; 855():252-261. PubMed ID: 31085238
[TBL] [Abstract][Full Text] [Related]
14. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
Xu B; Zhao Y; Wang X; Gong P; Ge W
Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927
[TBL] [Abstract][Full Text] [Related]
15. Mebendazole exhibits potent anti-leukemia activity on acute myeloid leukemia.
He L; Shi L; Du Z; Huang H; Gong R; Ma L; Chen L; Gao S; Lyu J; Gu H
Exp Cell Res; 2018 Aug; 369(1):61-68. PubMed ID: 29750898
[TBL] [Abstract][Full Text] [Related]
16. The simultaneous inhibition of the mTOR and MAPK pathways with Gnetin-C induces apoptosis in acute myeloid leukemia.
Espinoza JL; Elbadry MI; Taniwaki M; Harada K; Trung LQ; Nakagawa N; Takami A; Ishiyama K; Yamauchi T; Takenaka K; Nakao S
Cancer Lett; 2017 Aug; 400():127-136. PubMed ID: 28456658
[TBL] [Abstract][Full Text] [Related]
17. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
[TBL] [Abstract][Full Text] [Related]
18. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
[TBL] [Abstract][Full Text] [Related]
19. Glucopsychosine increases cytosolic calcium to induce calpain-mediated apoptosis of acute myeloid leukemia cells.
Angka L; Lee EA; Rota SG; Hanlon T; Sukhai M; Minden M; McMillan EM; Quadrilatero J; Spagnuolo PA
Cancer Lett; 2014 Jun; 348(1-2):29-37. PubMed ID: 24631520
[TBL] [Abstract][Full Text] [Related]
20. t(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt.
Imai N; Shikami M; Miwa H; Suganuma K; Hiramatsu A; Watarai M; Satoh A; Itoh M; Imamura A; Mihara H; Nitta M
Br J Haematol; 2006 Dec; 135(5):673-82. PubMed ID: 17107349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
